TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11923038

Group type: EXPERIMENTAL
Intervention: High-fat meal (760 calories)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (non-cheese pizza)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-fat meal with vitamin E (800 IU) and ascorbic acid (1,000 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal with vitamin E (800 IU) and ascorbic acid (1,000 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal
Number of subjects: 40
Study: 9577931

Group type: EXPERIMENTAL
Intervention: Low-frequency electromagnetic fields (50 Hz) of 0.2 microT-6.6 microT
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Exposure to low-frequency electromagnetic fields (50 Hz)
Number of subjects: 13
Study: 8126869

Group type: EXPERIMENTAL
Intervention: Endothelialized grafts
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control grafts (untreated polytetrafluoroethylene prosthesis)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Endothelialized group
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 2817745

Group type: EXPERIMENTAL
Intervention: CT scanning
Number of subjects: 35
Study: 236528

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31175963

Group type: EXPERIMENTAL
Intervention: Mobile cooperation intervention
Number of subjects: 52
Study: 27815524

Group type: EXPERIMENTAL
Intervention: Electronic adherence monitoring with daily reminder alarms and feedback in the clinic regarding ICS use
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care arm with adherence monitoring alone
Number of subjects: 90
Study: 26527777

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Vismodegib (GV)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Gemcitabine plus Placebo (GP)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both GV and GP
Number of subjects: 106
Study: 22910302

Group type: EXPERIMENTAL
Intervention: Indapamide slow release 1.5mg ± perindopril 2‐4 mg
Number of subjects: 3845

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3845
Study: 21546378

Group type: EXPERIMENTAL
Intervention: Microlaparoscopic hernia repair using 2‐mm instrument sets and small diameter scopes
Number of subjects: 100
Study: 19451556

Group type: EXPERIMENTAL
Intervention: Telmisartan, 80 mg/d (n = 2954)
Number of subjects: 5927

Group type: COMPARATOR
Intervention: Placebo (n = 2972)
Number of subjects: 5927

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 5927

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5927
Study: 16709650

Group type: EXPERIMENTAL
Intervention: Ex + Lo CHO
Number of subjects: 18

Group type: COMPARATOR
Intervention: Lo CHO
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ex + Norm CHO
Number of subjects: 18

Group type: COMPARATOR
Intervention: Norm CHO
Number of subjects: 18
Study: 15462099

Group type: EXPERIMENTAL
Intervention: Intravenous 1,25(OH)2D3 therapy (1-2 microg thrice a week for 12 weeks, mean dose 4.5 microg/week)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (14 healthy volunteers matched for age, sex, and BMI)
Number of subjects: 8
Study: 16420079

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) alone
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Exposure in vivo with response prevention (ERP) alone
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) with fluvoxamine
Number of subjects: 102
Study: 10357748

Group type: EXPERIMENTAL
Intervention: Prenatal supplements containing 60 mg Fe, 250 microg folate, and 15 mg Zn
Number of subjects: 1295

Group type: COMPARATOR
Intervention: Prenatal supplements containing 60 mg Fe and 250 microg folate without Zn
Number of subjects: 1295
Study: 7580187

Group type: EXPERIMENTAL
Intervention: Moderately suprathreshold ECT (2.5T)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Barely suprathreshold ECT (T)
Number of subjects: 25
Study: 2272864

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 60
Study: 6153164

Group type: EXPERIMENTAL
Intervention: Direct fluorescent antibody technique
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PAS staining
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional methods (H & E, Trichrome, PTAH)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Indirect fluorescent antibody technique (ethanol-fixed tissues)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Indirect fluorescent antibody technique (formalin-fixed tissues)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Metronidazole treatment
Number of subjects: 19
Study: 30760655

Group type: EXPERIMENTAL
Intervention: Renal Denervation (RDN)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combined RDN and crossover group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (standard pharmacologic therapy)
Number of subjects: 41
Study: 27932292

Group type: EXPERIMENTAL
Intervention: Graduated Compression Stockings (GCS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo sock
Number of subjects: 18
Study: 27588209

Group type: EXPERIMENTAL
Intervention: High-flavanol dark chocolate (HFDC; 1064mg of flavanols/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-flavanol dark chocolate (LFDC; 88mg of flavanols/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High-flavanol dark chocolate (HFDC)
Number of subjects: 32
Study: 24831394

Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol/ipratropium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22518045

Group type: EXPERIMENTAL
Intervention: Opt-in consent approach
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Opt-out consent approach
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 1129
Study: 19170904

Group type: EXPERIMENTAL
Intervention: RVOT
Number of subjects: 87

Group type: COMPARATOR
Intervention: RVA
Number of subjects: 87
Study: 17479527

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) for 24 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Attention placebo control (APC) for 24 weeks
Number of subjects: 24
Study: 15611537

Group type: EXPERIMENTAL
Intervention: Patient Controlled Analgesia (PCA) with morphine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Nurse delivered analgesia with morphine via conventional route
Number of subjects: 86
Study: 12522833

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 9658759

Group type: EXPERIMENTAL
Intervention: Patients with a history of alcoholic liver disease
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Patients with schistosomiasis Japonica infection
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Patients with Budd-Chiari syndrome
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Patients positive for anti-HBc antibody
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Patients positive for autoantibodies
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Histopathologic examination of liver
Number of subjects: 22
Study: 7641721

Group type: EXPERIMENTAL
Intervention: Alfentanil bolus (30 micrograms kg-1) followed by infusion of placebo (group II)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alfentanil infusion at the rate of 10 micrograms kg-1 h-1 (group III)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alfentanil infusion at the rate of 20 micrograms kg-1 h-1 (group IV)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alfentanil infusion at the rate of 40 micrograms kg-1 h-1 (group V)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo bolus followed by placebo infusion (group I)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alfentanil (any dosage) during abdominal surgery
Number of subjects: 100
Study: 2666710

Group type: EXPERIMENTAL
Intervention: Finoptin (10 mg intravenous)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Phosphobion (10 mg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Finoptin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Phosphobion
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Finoptin and Phosphobion
Number of subjects: 47
Study: 31945069

Group type: EXPERIMENTAL
Intervention: Messages reminding respondents of familial support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presentation of additional visual information
Number of subjects: 0
Study: 30508547

Group type: EXPERIMENTAL
Intervention: 300 mg secukinumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150 mg secukinumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28212060

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks)
Number of subjects: 542

Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice of paclitaxel, docetaxel, or vinflunine)
Number of subjects: 542
Study: 25749740

Group type: EXPERIMENTAL
Intervention: RawBMD
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: TPerc
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: RawT
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: TSamp
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: TRef
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Spine
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Femoral neck
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Total hip
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Change from baseline (CB)
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Percentage change from baseline (%CB)
Number of subjects: 774
Study: 25092484

Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes PULSE Programme for Men (6-month, self-administered, gender-tailored lifestyle intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes PULSE Programme for Men
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 22980300

Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive strategy
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 1059
Study: 19559374

Group type: EXPERIMENTAL
Intervention: Immediate postoperative radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salvage radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate postoperative or salvage radiotherapy with androgen deprivation therapy
Number of subjects: 0
Study: 17562639

Group type: EXPERIMENTAL
Intervention: Partner-delivered foot reflexology
Number of subjects: 86

Group type: COMPARATOR
Intervention: Usual care plus attention (control)
Number of subjects: 86
Study: 15155330

Group type: EXPERIMENTAL
Intervention: Methadone 20 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Fentanyl 10 microg/kg
Number of subjects: 43
Study: 11252624

Group type: EXPERIMENTAL
Intervention: Generalized linear mixed model (GLMM) methodology with Cox partial likelihood for survival analysis.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Residual maximum likelihood (REML) estimators of the variance component.
Number of subjects: 0
Study: 9486490

Group type: EXPERIMENTAL
Intervention: i.v. tacrolimus
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: p.o. tacrolimus
Number of subjects: 31

Group type: COMPARATOR
Intervention: methylprednisolone or methotrexate co-administration
Number of subjects: 31
Study: 7993858

Group type: EXPERIMENTAL
Intervention: Blood transfused group
Number of subjects: 131

Group type: COMPARATOR
Intervention: Nonblood transfused group
Number of subjects: 131
Study: 2666662

Group type: EXPERIMENTAL
Intervention: P6 electroacupuncture (10 Hz applied for 5 min)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Dummy acupuncture (ACP) point
Number of subjects: 130
Study: 4706914

Group type: EXPERIMENTAL
Intervention: Cholestyramine (12 g)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lignin
Number of subjects: 14
Study: 31512497

Group type: EXPERIMENTAL
Intervention: CPI-613 plus modified FOLFIRINOX (mFFX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFIRINOX (FFX)
Number of subjects: 0
Study: 28385654

Group type: EXPERIMENTAL
Intervention: Pre-operative Rehabilitation Program (PRP) for one week (IG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine preoperative preparation for one week (CG)
Number of subjects: 80
Study: 26366058

Group type: EXPERIMENTAL
Intervention: Pasireotide LAR (60 mg every 28 days)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Octreotide LAR (40 mg every 28 days)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Number of subjects: 88

Group type: COMPARATOR
Intervention: Octreotide LAR
Number of subjects: 88
Study: 23800793

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (20 min, 1 mA) over the left swallowing motor cortex
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (20 min, 1 mA) over the right swallowing motor cortex
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 21
Study: 21665191

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Talking control (TC)
Number of subjects: 204
Study: 18607381

Group type: EXPERIMENTAL
Intervention: 6 nmol kg(‐1) PP
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 6 nmol kg(‐1) PYY(3‐36)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 3 nmol kg(‐1) PP+3 nmol kg(‐1) PYY(3‐36)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 30 nmol kg(‐1) PP
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 30 nmol kg(‐1) PYY(3‐36)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 30 nmol kg(‐1) PP+30 nmol kg(‐1) PYY(3‐36)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PP+PYY
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PP
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PYY
Number of subjects: 26
Study: 15647641

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 14

Group type: COMPARATOR
Intervention: Somatostatin vs Octreotide
Number of subjects: 14
Study: 12107722

Group type: EXPERIMENTAL
Intervention: Mosapride (5 mg orally three times a day)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Mosapride
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Mosapride (8 weeks treatment)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 10442492

Group type: EXPERIMENTAL
Intervention: Relapse (RL) group
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Remission (RM) group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 42
Study: 7598058

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (15,000 and 30,000 micrograms retinol equivalents or 50,000 and 100,000 IU)
Number of subjects: 11918

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11918
Study: 2193172

Group type: EXPERIMENTAL
Intervention: Oral bacillus Calmette-Guerin (200 mg, 3 times each week)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Intravesical plus percutaneous bacillus Calmette-Guerin (50 mg weekly for 6 weeks, then at 8, 10, and 12 weeks, then at 6 months and every 6 months thereafter)
Number of subjects: 88
Study: 365324

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 200
Study: 30479028

Group type: EXPERIMENTAL
Intervention: Permanent polymer drug-eluting stents (PP-DES)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Biodegradable polymer drug-eluting stents (BP-DES)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both PP-DES and BP-DES
Number of subjects: 50
Study: 27622507

Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (OCV)
Number of subjects: 71900
Study: 24952227

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FDG-PET analysis 3-6 months after RFA
Number of subjects: 20
Study: 22300972

Group type: EXPERIMENTAL
Intervention: Blunt tipped chest tube
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sharp tipped chest tube
Number of subjects: 100
Study: 19731119

Group type: EXPERIMENTAL
Intervention: 2.5 mg tibolone + one Cal+D tablet (500 mg calcium and 200 IU vitamin D) daily
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen + 2.5 mg medroxyprogesterone (CEE/MPA) + one Cal+D tablet daily
Number of subjects: 140

Group type: COMPARATOR
Intervention: one Cal+D tablet daily
Number of subjects: 140
Study: 18503924

Group type: EXPERIMENTAL
Intervention: Computer-guided glucose management system (CG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard paper-based insulin protocol
Number of subjects: 40
Study: 15922980

Group type: EXPERIMENTAL
Intervention: Mifepristone 5 mg daily for 1 year
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mifepristone 10 mg daily for 1 year
Number of subjects: 40
Study: 15168910

Group type: EXPERIMENTAL
Intervention: MDMA users
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MDMA users (greater use)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Heavy MDMA users (>= 50 times)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 50
Study: 11045137

Group type: COMPARATOR
Intervention: β-blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8958387

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) prophylactic treatment for 2 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: PF4-heparin ELISA test
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Bilateral venography
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Daily platelet count
Number of subjects: 37
Study: 1300565

Group type: EXPERIMENTAL
Intervention: Interferon alpha (Wellferon)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Prednisone pretreatment
Number of subjects: 44
Study: 3862040

Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine gluconate mouth rinse, twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 16
Study: 30463820

Group type: EXPERIMENTAL
Intervention: Atomization inhalation of terbutaline followed by nebulized inhalation of budesonide
Number of subjects: 240

Group type: COMPARATOR
Intervention: Atomized inhalation of mixed liquid of terbutaline and budesonide
Number of subjects: 240
Study: 27312903

Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol fixed combination (DTFC)
Number of subjects: 0
Study: 24867917

Group type: EXPERIMENTAL
Intervention: Positive psychology intervention (n = 20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Attention control (education) intervention (n = 19)
Number of subjects: 39
Study: 22722632

Group type: EXPERIMENTAL
Intervention: GPi DBS
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: STN DBS
Number of subjects: 159
Study: 19773416

Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment
Number of subjects: 395
Study: 17494985

Group type: EXPERIMENTAL
Intervention: Vignette with diagnostic/psychiatric labelling
Number of subjects: 120

Group type: COMPARATOR
Intervention: Vignette without diagnostic/psychiatric labelling
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vignette with symptoms of ADHD (gender-neutral peer)
Number of subjects: 120
Study: 15967511

Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation plus sertraline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sertraline monotherapy
Number of subjects: 24
Study: 11812715

Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 105

Group type: COMPARATOR
Intervention: 0.125% levobupivacaine
Number of subjects: 105

Group type: COMPARATOR
Intervention: 0.0625% levobupivacaine
Number of subjects: 105
Study: 10568861

Group type: EXPERIMENTAL
Intervention: Intraarticular morphine (3 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline (3 ml)
Number of subjects: 44
Study: 8908288

Group type: EXPERIMENTAL
Intervention: OK-432 (immunotherapy)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control (no OK-432)
Number of subjects: 109
Study: 1299793

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 56
Study: 6381015

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 30718625

Group type: EXPERIMENTAL
Intervention: 16Δ base‐out prism condition
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: -2.50D spherical lenses condition
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control normal viewing condition
Number of subjects: 21
Study: 30260736

Group type: EXPERIMENTAL
Intervention: Constant laser irradiation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interval laser irradiation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide disinfection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 27442314

Group type: EXPERIMENTAL
Intervention: Omega-3 group (4 softgels containing 1680 mg eicosapentaenoic acid/560 mg docosahexaenoic acid daily for 12 weeks)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Omega-3 group
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (3136 mg of linoleic acid daily for 12 weeks)
Number of subjects: 105
Study: 23548420

Group type: EXPERIMENTAL
Intervention: Intramyocardial Multiple Precision Administration of Mononuclear Bone Marrow Cells (MBMC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21926634

Group type: EXPERIMENTAL
Intervention: Once-daily efavirenz doses of 200, 250, 300, 350 mg based on weight bands
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Once-daily efavirenz doses
Number of subjects: 41
Study: 19346974

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 39